Order Article Reprints

Friedli C, Salmen A, Hoepner R, Achtnichts L, Bigi S, Derfuss T, Gobbi C, Kamber N, Kamm CP, Kuhle J, et al. Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022. Clinical and Translational Neuroscience. 2023; 7(1):2. https://doi.org/10.3390/ctn7010002

Friedli, Christoph, Anke Salmen, Robert Hoepner, Lutz Achtnichts, Sandra Bigi, Tobias Derfuss, Claudio Gobbi, Nicole Kamber, Christian P. Kamm, Jens Kuhle, and et al. 2023. "Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022" Clinical and Translational Neuroscience 7, no. 1: 2. https://doi.org/10.3390/ctn7010002

Friedli, C., Salmen, A., Hoepner, R., Achtnichts, L., Bigi, S., Derfuss, T., Gobbi, C., Kamber, N., Kamm, C. P., Kuhle, J., Lalive, P., Müller, S., Papadopoulou, A., Pot, C., Zecca, C., & Chan, A., on behalf of the Scientific Advisory Board of the Swiss Multiple Sclerosis Society and the Swiss Neurological Society. (2023). Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022. Clinical and Translational Neuroscience, 7(1), 2. https://doi.org/10.3390/ctn7010002